ACE2 and COVID-19: Phase II clinical trials were completed in January 2021 for the recombinant human angiotensin-converting enzyme 2 (rhACE2), APN01, as an intravenous treatment for patients with COVID-19 to block viral entry and decrease viral replication (ClinicalTrials.gov, clinical trial ID: NCT04335136).